keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic prostatic cancer clinical treatment

keyword
https://www.readbyqxmd.com/read/29666893/pitfalls-in-bone-density-monitoring-in-prostate-cancer-during-anti-resorptive-treatment
#1
Y-M Cheung, S K Ramchand, M Grossmann
A 74-year-old man presented to the Andrology Clinic for management of potential complications of androgen deprivation therapy for prostate cancer. He had a rising prostate-specific antigen with a concurrent rise in alkaline phosphatase and bone remodeling markers. This was despite treatment with a radical prostatectomy, androgen deprivation, and anti-resorptive therapy. A follow-up dual-energy X-ray absorptiometry scan revealed a marked increase in his bone mineral density at both the lumbar spine and femoral neck...
April 17, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29666832/structure-and-function-analysis-in-circulating-tumor-cells-using-nanotechnology-to-study-nuclear-size-in-prostate-cancer
#2
REVIEW
Nu Yao, Yu-Jen Jan, Shirley Cheng, Jie-Fu Chen, Leland Wk Chung, Hsian-Rong Tseng, Edwin M Posadas
Professor Donald Coffey and his laboratory pioneered studies showing the relationships between nuclear shape and cellular function. In doing so, he and his students established the field of nuclear morphometry in prostate cancer. By using perioperative tissues via biopsies and surgical sampling, Dr. Coffey's team discovered that nuclear shape and other pathologic features correlated with clinical outcome measures. Cancer cells also exist outside of solid tumor masses as they can be shed from both primary and metastatic lesions into the circulatory system...
2018: American Journal of Clinical and Experimental Urology
https://www.readbyqxmd.com/read/29663669/preliminary-efficacy-and-tolerability-of-chemohormonal-therapy-in-metastatic-hormone-na%C3%A3-ve-prostate-cancer-the-first-real-life-experience-in-asia
#3
Darren M C Poon, Tim Chan, Kuen Chan, Michelle Chan, Eric K C Lee, Kitty Law, Daisy Lam
INTRODUCTION: A substantial survival benefit with chemohormonal therapy has been proven by the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the standard of care for patients with metastatic hormone-naïve prostate cancer (mHSPC). However, because its clinical efficacy and tolerability in Asian patients remains uncertain, this study aims to evaluate preliminary results of its use in Hong Kong. METHODS: The clinical records of mHSPC patients treated with chemohormonal therapy from all six public oncology centers in Hong Kong between January 2015 and July 2016 were reviewed...
April 16, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29661653/radium-223-in-the-treatment-of-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer-review-and-procedure
#4
J Orcajo-Rincon, A P Caresia-Aróztegui, M Del Puig Cózar-Santiago, J R García-Garzón, M de Arcocha-Torres, R C Delgado-Bolton, M J García-Velloso, S Alvarez-Ruiz, A M García-Vicente
Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223 Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease...
April 13, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29658595/huaier-suppresses-proliferative-and-metastatic-potential-of-prostate-cancer-pc3-cells-via-downregulation-of-lamin-b1-and-induction-of-autophagy
#5
Ailin Yang, Yanan Zhao, Ying Wang, Xiaojun Zha, Yunfang Zhao, Pengfei Tu, Zhongdong Hu
Prostate cancer is one of the most common malignancies occurring in males. Although large advances have been made in the pathogenesis of prostate cancer, the development of drugs with high efficacy and low toxicity for the treatment of prostate cancer is urgently needed. Recently, more and more attention has been paid to the antitumor effect of Traditional Chinese Medicine (TCM) worldwide. Trametes robiniophila Murr. (Huaier) has been applied as a type of TCM drug for ~1,600 years. Huaier exhibits excellent clinical efficacy in the treatment of cancer, including prostate cancer...
April 5, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29656854/radical-prostatectomy-in-metastatic-castration-resistant-prostate-cancer-feasibility-safety-and-quality-of-life-outcomes
#6
Chad A Reichard, Justin R Gregg, Mary F Achim, Ana M Aparicio, Curtis A Pettaway, Louis L Pisters, John F Ward, John W Davis, Brian F Chapin
Ongoing prospective studies are evaluating treatment of the primary tumor in men with de novo metastatic prostate cancer (PCa). One potential benefit is prevention of morbidity from local progression. Thus, local therapy may be best applied selectively to men with local progression once resistance to first-line therapies has occurred. Here, we gather support for the hypothesis that radical prostatectomy (RP) is safe and preserves quality of life (QOL) when applied in men with metastatic castration-resistant PCa (mCRPC)...
April 12, 2018: European Urology
https://www.readbyqxmd.com/read/29651712/prognostic-impact-of-nodal-relapse-in-definitive-prostate-only-irradiation
#7
Mauro Loi, Luca Incrocci, Isacco Desideri, Pierluigi Bonomo, Beatrice Detti, Gabriele Simontacchi, Daniela Greto, Emanuela Olmetto, Giulio Francolini, Icro Meattini, Lorenzo Livi
BACKGROUND: Whole pelvic irradiation in prostate cancer patients might prevent metastatic spread of cancer cells through lymphatic drainages in patients eligible for definitive radiotherapy, but its use has declined in the last decades in favor of prostate-only irradiation (POI). The aim of our study is to assess the incidence of pelvic lymph nodal relapse and outcome in prostate cancer patients receiving POI. MATERIALS AND METHODS: Data from 207 consecutive patients were collected...
April 12, 2018: La Radiologia Medica
https://www.readbyqxmd.com/read/29651569/external-radiation-exposure-excretion-and-effective-half-life-in-177-lu-psma-targeted-therapies
#8
J Kurth, B J Krause, S M Schwarzenböck, L Stegger, M Schäfers, K Rahbar
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with 177 Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. RESULTS: In total, 50 patients with mCRPC and treated with 177 Lu-PSMA-617 (mean administered activity 6...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29649281/classification-for-long-term-survival-in-oligometastatic-patients-treated-with-ablative-radiotherapy-a-multi-institutional-pooled-analysis
#9
Julian C Hong, Diandra N Ayala-Peacock, Jason Lee, A William Blackstock, Paul Okunieff, Max W Sung, Ralph R Weichselbaum, Johnny Kao, James J Urbanic, Michael T Milano, Steven J Chmura, Joseph K Salama
BACKGROUND: Radiotherapy is increasingly used to treat oligometastatic patients. We sought to identify prognostic criteria in oligometastatic patients undergoing definitive hypofractionated image-guided radiotherapy (HIGRT). METHODS: Exclusively extracranial oligometastatic patients treated with HIGRT were pooled. Characteristics including age, sex, primary tumor type, interval to metastatic diagnosis, number of treated metastases and organs, metastatic site, prior systemic therapy for primary tumor treatment, prior definitive metastasis-directed therapy, and systemic therapy for metastasis associated with overall survival (OS), progression-free survival (PFS), and treated metastasis control (TMC) were assessed by the Cox proportional hazards method...
2018: PloS One
https://www.readbyqxmd.com/read/29644451/emerging-therapies-in-metastatic-prostate-cancer
#10
REVIEW
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29629866/prognostic-and-predictive-clinical-factors-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#11
Daniel W Yokom, John Stewart, Nimira S Alimohamed, Eric Winquist, Scott Berry, Stacey Hubay, Jean-Baptiste Lattouf, Helene Leonard, Carla Girolametto, Fred Saad, Srikala S Sridhar
INTRODUCTION: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel. METHODS: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed...
April 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29626548/clinical-indications-for-and-the-future-of-circulating-tumor-cells
#12
Dominic H Moon, Daniel P Lindsay, Seungpyo Hong, Andrew Z Wang
Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making...
April 4, 2018: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29623850/treatment-of-metastatic-castration-resistant-docetaxel-resistant-prostate-cancer-a-systematic-review-of-literature-with-a-network-meta-analysis-of-randomized-clinical-trials
#13
Davide Tassinari, Chiara Cherubini, Britt Roudnas, Emiliano Tamburini, Fabrizio Drudi, Emanuela Bianchi, Manuela Fantini, Francesco Montanari, Sergio Sartori
INTRODUCTION: To compare the efficacy of abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer. METHODS: An indirect comparison of overall survival (OS) and time to PSA progression among abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 was performed with a network meta-analysis. OS in the entire population of patients was the primary end point. OS in ECOG 0-1/2, BPI-SF≤4/>4, pretreated with 1 or 2 courses of chemotherapy, age≤65/>65 patients, patients with only bone metastases or bone and visceral metastases, and time to PSA progression were the secondary end points...
April 4, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29620284/enrichment-and-mutation-detection-of-circulating-tumor-cells-from-blood-samples
#14
Ruqin Kou, Jian Zhao, Priya Gogoi, Shannon Carskadon, Will Chow, Clara Hwang, Nallasivam Palanisamy, Conrad Leung, Yixin Wang
The potential of circulating tumor cells (CTCs) in the diagnosis and prognosis of cancer patients has become increasingly attractive. However, molecular analysis of CTCs is hindered by low sensitivity and a high level of background leukocytes in CTC enrichment technologies. We have developed a novel protocol using a microfluidic device, which enriches and retrieves CTCs from blood samples. The principle of CTC capturing is that tumor cells are larger and less deformable than normal blood cells. To evaluate the potential of utilizing Celsee PREP100 in CTC molecular analysis, we prepared prostate cancer cell lines PC3 and LNCaP, retrieved the captured cells and analyzed them using PCR amplicon sequencing...
March 30, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29618107/incidence-and-time-of-onset-of-osseous-pseudoprogression-in-patients-with-metastatic-spine-disease-from-renal-cell-or-prostate-carcinoma-after-treatment-with-stereotactic-body-radiation-therapy
#15
Pejman Jabehdar Maralani, Kathleen Winger, Sean Symons, Matylda Machnowska, Chinthaka Heyn, Ali Helmi, Aimee Chan, Chia-Lin Tseng, Arjun Sahgal
BACKGROUND: Tumor osseous pseudoprogression (PP), defined as an imaging-based transient increase in tumor size following treatment, was recently described in patients with spinal metastases following stereotactic body radiation therapy. Distinguishing PP from true tumor progression is critical. OBJECTIVE: To describe the incidence, time of onset, and time range of PP following stereotactic body radiation therapy in patients treated for spinal metastases from either prostate cancer (PC) or renal cell carcinoma (RCC), and associated predictive factors...
March 29, 2018: Neurosurgery
https://www.readbyqxmd.com/read/29616555/improvement-in-therapeutic-efficacy-and-reduction-in-cellular-toxicity-introduction-of-a-novel-anti-psma-conjugated-hybrid-antiandrogen-nanoparticle
#16
Chellappagounder Thangavel, Maryna Perepelyuk, Ettickan Boopathi, Yi Liu, Steven Polischak, Deepak A Deshpande, Khadija Rafiq, Adam P Dicker, Karen E Knudsen, Sunday A Shoyele, Robert B Den
Second generation antiandrogens have improved overall survival for men with metastatic castrate resistant prostate cancer; however, the antiandrogens result in suppression of androgen receptor (AR) activity in all tissues resulting in dose limiting toxicity. We sought to overcome this limitation through encapsulation in a prostate specific membrane antigen (PSMA)-conjugated nanoparticle. We designed and characterized a novel nanoparticle containing an antiandrogen, enzalutamide. Selectivity and enhanced efficacy was achieved through coating the particle with PSMA...
April 4, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29611275/clinical-and-prognostic-significance-of-changes-in-haemoglobin-level-during-one-year-of-androgen-deprivation-treatment-for-hormone-na%C3%A3-ve-bone-metastatic-prostate-cancer
#17
Maria Ebbinge, Anders Berglund, Eberhard Varenhorst, Per Olov Hedlund, Gabriel Sandblom
OBJECTIVE: To estimate the strength of change in haemoglobin levels during one year of ADT as a predictor of survival in hormone naive prostate cancer patients with bone metastases. MATERIAL AND METHODS: The patients included in this study were taken from the randomised trial (No.5) carried out by the Scandinavian Prostate Cancer Group (SPCG), comparing parenteral oestrogen with total androgen blockade (TAB) in hormone-naive metastatic prostate cancer (category M1b)...
April 2, 2018: BJU International
https://www.readbyqxmd.com/read/29606109/neoadjuvant-degarelix-with-or-without-apalutamide-followed-by-radical-prostatectomy-for-intermediate-and-high-risk-prostate-cancer-arneo-a-randomized-double-blind-placebo-controlled-trial
#18
Lorenzo Tosco, Annouschka Laenen, Thomas Gevaert, Isabelle Salmon, Christine Decaestecker, Elai Davicioni, Christine Buerki, Frank Claessens, Johan Swinnen, Karolien Goffin, Raymond Oyen, Wouter Everaerts, Lisa Moris, Gert De Meerleer, Karin Haustermans, Steven Joniau
BACKGROUND: Recent retrospective data suggest that neoadjuvant androgen deprivation therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel androgen receptor pathway inhibitors are nowadays available for treatment of metastatic PCa and these compounds are promising for early stage disease. Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor. The combination of apalutamide with degarelix, an LHRH antagonist, could increase the efficacy compared to degarelix alone...
April 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29603585/localized-prostate-cancer-in-elderly-men-aged-80-89-findings-from-a-population-based-registry
#19
S Vatandoust, G Kichenadasse, M O'Callaghan, A D Vincent, T Kopsaftis, S Walsh, M Borg, C S Karapetis, K Moretti
OBJECTIVES: To investigate the rate of death due to Prostate Cancer (PCa) and disease characteristics in patients diagnosed with Localized Prostate Cancer (LPCa) at age 80-89 years in comparison with men diagnosed at age 70-79. PATIENTS AND METHODS: This is a retrospective study of data from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC). Included were men diagnosed between 2005 and 2014, aged ≥70 with no evidence of metastatic disease at presentation...
March 30, 2018: BJU International
https://www.readbyqxmd.com/read/29594021/men-with-a-susceptibility-to-prostate-cancer-and-the-role-of-genetic-based-screening
#20
REVIEW
Rosalind Eeles, Holly Ni Raghallaigh
Prostate cancer is the second most common malignancy affecting men worldwide, and the commonest affecting men of African descent. Significant diagnostic and therapeutic advances have been made in the past decade. Improvements in the accuracy of prostate cancer diagnosis include the uptake of multi-parametric MRI and a shift towards targeted biopsy. We also now have more life-prolonging systemic and hormonal therapies for men with advanced disease at our disposal than ever before. However, the development of robust screening tools and targeted screening programs has not followed at the same pace...
February 2018: Translational Andrology and Urology
keyword
keyword
104201
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"